Key Takeaways For J&J From Goldman Sachs Healthcare Conference

At the Goldman Sachs Healthcare Conference on June 8th, Mr.Dominic Caruso (Executive VP And CFO, Johnson & Johnson) identified a strong pipeline of drugs and Mitral Valve Robotics Devices as major drivers that could drive future growth of Johnson & Johnson.[1] We believe Mitral Valve Robotics provides a big growth opportunity for J&J if concerted efforts and investments are made in that sector.

[1] Johnson & Johnson (JNJ) Presents at 2016 Goldman Sachs 37th Annual Global Healthcare Conference (Transcript), Seeking Alpha, June 08,2016

[2] Structural Heart Disease, Micro Interventional Devices, 14 June, 2016

Have more questions about Johnson & Johnson? See the links below.

• Drugs, Devices, Consumer: What’s Johnson & Johnson’s Revenue and Earnings breakdown?
• How Increased Focus On Pharmaceuticals In The Last 5 Years Has Helped J&J?
• By How Much Can J&J’s Revenue And EBITDA Grow Over The Next 3 Years?
• What Percentage Of Its Revenue Could J&J Lose Solely Due To Patent Losses Over The Next 5 Years?
• If Remicade Biosimilar Hits The U.S. Market In 2017, Does J&J Face Any Meaningful EPS Decline?
• Considering Recent Divestitures, Should J&J Trim Its Medical Devices Segment Further?
• Despite The Revenue Fall, J&J’s Business Has A Silver Lining
• Three Things To Watch Out For J&J This Year
• Here Is Why J&J Could See Growth As It Reports Its Q1 2016 Results
• Why We Are Slightly Bullish On J&J?

Notes:

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)

Get Trefis Technology

A Message From Trefis Marketing

Download our eBook “Close More Sales:  How to Avoid ‘No Decision'” and learn

• The key reason why sales don’t close
• One essential way to close more sales and do that faster
• Specific steps you can take to improve immediately

Click here